Zhongchao Introduces New Line of Business Focusing on Tumor and Rare Disease Patient Management

According to China's National Health Commission, there are around 20 million patients with uncommon diseases in the country.

FREMONT, CA: Zhongchao, healthcare services company providing online healthcare information, professional training and educational services, has declared the launch of the patient management service focusing on the professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin Medical Technology Co("Zhongxin").

Zhongchao has been closely following new tumor and rare illness studies in China and around the world. According to the World Health Organization's International Agency for Research on Cancer data, there will be roughly 19.29 million new cancer cases and 10 million cancer deaths worldwide in 2020. In 2020, China had around 4.57 million new cancer cases, accounting for approximately 23.7 percent of total cancer cases worldwide. According to China's National Health Commission, there are around 20 million patients with uncommon diseases in the country. Medical treatment markets for both cancer and rare disorders have grown in tandem with the growing number of patients.

In addition to drug development and more advanced medical treatment options, the Company has recognized that patients' active participation in treatment is critical to achieving better overall treatment outcomes such as higher chemotherapy completion rates, lower rehospitalization risk, and longer survival time. Many international pharmaceutical corporations have recognized the importance of such investments by making strategic investments in drug development and patient management programs.